GLP-3 RT + Cagrilintide Research Guide: Triple Agonist + Amylin
This combination vial pairs GLP-3 RT (triple agonist) with Cagrilintide (amylin analog) — a leading-edge metabolic-research combination.
Component mechanisms
GLP-3 RT — triple receptor agonist with once-weekly ~6-day half-life. See the GLP-3 RT research guide for the full mechanism breakdown.
Cagrilintide — long-acting amylin analog that engages amylin receptors in the area postrema, prolonging satiety and slowing gastric emptying independently of GLP-1 signaling.
Sourcing & purity
Research-grade material should be ≥99% pure by HPLC with peptide content confirmed via mass spectrometry. Redline Bio material ships with batch documentation; independent third-party COAs are published on the lab reports page as testing returns.
Compliance reminder
Sold and distributed for laboratory research use only. Not approved by the FDA for human consumption, diagnosis, treatment, or cure of any disease. Researchers are responsible for compliance with all applicable institutional, state, and federal regulations.
Frequently asked questions
What is in the vial?
Each 10 mg vial contains 5 mg GLP-3 RT and 5 mg Cagrilintide co-lyophilized.
Why combine incretin + amylin?
The two pathways produce complementary satiety and weight-management signals in metabolic research. GLP-3 RT adds triple-agonist metabolic effects; Cagrilintide extends satiety via amylin-receptor engagement in the area postrema.